Description of the active substance:
This information is a reference and it is not enough that the drug was prescribed by a doctor. .
The blocker of histamine H 1 -receptors. Fexofenadine is a pharmacologically active metabolite of terfenadine. Does not have a sedative effect.
The antihistamine effect is manifested after 1 hour, reaching a maximum after 6 hours and lasting for 24 hours. After 28 days of admission, there was no addiction.
It was found that if administered orally in a dose range of 10 mg to 130 mg, the effectiveness of fexofenadine is dose-dependent.
After oral administration, it is rapidly absorbed from the digestive tract, C max is determined after 1-3 hours. The average value of C max after taking 180 mg is approximately 494 ng / ml, and after taking 120 mg - 427 ng / ml. Binding to plasma proteins - 60-70%. T 1/2 after repeated intake - 11-15 hours. Excreted in breast milk. 5% of the dose is subject to partial extrahepatic metabolism. It is excreted mainly with bile (80%), 10% is excreted by the kidneys unchanged.
Elimination of symptoms associated with seasonal allergic rhinitis, symptomatic treatment of chronic urticaria.
For adults and children over 12 years of age, the daily dose is 120-180 mg (1 time / day).
Possible: headache, drowsiness, dizziness, fatigue, nausea, lethargy, increased fatigue.
Pregnancy, lactation, children under 6 years of age, hypersensitivity to fexofenadine.
PREGNANCY AND LACTATION
Fexofenadine is contraindicated in pregnancy and lactation (breastfeeding).
Fexofenadine penetrates into breast milk. If fexofenadine is needed during lactation, the question of stopping breastfeeding should be addressed.
APPLICATION FOR FUNCTIONS OF THE LIVER
Use with caution in patients with renal insufficiency.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in patients with hepatic insufficiency.
APPLICATION FOR CHILDREN
The use of the drug in children younger than 6 years is not recommended.
APPLICATION IN ELDERLY PATIENTS
Use with caution in elderly patients.
Use with caution in elderly patients, in patients with renal or hepatic insufficiency.
The efficacy and safety of fexofenadine in children younger than 6 years have not been studied.
Impact on the ability to drive vehicles and manage mechanisms
Based on the pharmacodynamic profile and known side effects, it can be assumed that the effect of fexofenadine on the ability to drive vehicles and activities requiring increased concentration of attention is unlikely. In carrying out objective studies, it has been shown that fexofenadine does not significantly affect the functions of the central nervous system. Nevertheless, it is recommended to check the individual reaction before starting driving vehicles or other potentially hazardous activities.
Fexofenadine is not biotransformed in the liver and therefore does not interact with other drugs that undergo hepatic metabolism.
It has been shown that when fexofenadine is used together with erythromycin or ketoconazole, the concentration of fexofenadine in plasma increases 2-3 times, which is probably due to an increase in absorption from the gastrointestinal tract and a reduction in either excretion of bile or gastrointestinal secretion. There were no changes in the QT interval.
When taking antacids containing aluminum or magnesium 15 minutes prior to fexofenadine intake, a decrease in its bioavailability was observed, most likely due to binding in the gastrointestinal tract. The recommended interval between fexofenadine and antacids containing aluminum or magnesium hydroxide is 2 hours.
Does not interact with omeprazole, with drugs metabolized in the liver.